NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis $18.86 -0.01 (-0.05%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.60▼$19.5750-Day Range$16.62▼$20.8452-Week Range$13.48▼$32.60Volume769,583 shsAverage Volume623,708 shsMarket Capitalization$1.88 billionP/E RatioN/ADividend YieldN/APrice Target$58.97 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zai Lab alerts: Email Address Zai Lab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside212.7% Upside$58.97 Price TargetShort InterestBearish2.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.90Based on 6 Articles This WeekInsider TradingSelling Shares$1.12 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.76) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector553rd out of 936 stocksPharmaceutical Preparations Industry250th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZai Lab has only been the subject of 2 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.97% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Zai Lab has recently increased by 4.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 3.3 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Zai Lab this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat Follows2 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,116,043.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($2.76) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Zai Lab Stock (NASDAQ:ZLAB)Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More ZLAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Stock News HeadlinesJuly 4, 2024 | insidertrades.comZai Lab Limited (NASDAQ:ZLAB) Director William Lis Sells 10,397 SharesJuly 3, 2024 | insidertrades.comZai Lab Limited (NASDAQ:ZLAB) CEO Ying Du Sells 7,013 SharesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 28, 2024 | insidertrades.comYajing Chen Sells 2,154 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockJuly 26 at 8:04 AM | investorplace.comTrade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden GemJuly 21, 2024 | americanbankingnews.comFinancial Survey: Zai Lab (NASDAQ:ZLAB) and Incannex Healthcare (NASDAQ:IXHL)July 18, 2024 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Sees Large Volume IncreaseJuly 18, 2024 | americanbankingnews.comComparing Amicus Therapeutics (NASDAQ:FOLD) and Zai Lab (NASDAQ:ZLAB)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 11, 2024 | businesswire.comZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&DMay 22, 2024 | businesswire.comZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisMay 20, 2024 | markets.businessinsider.comZai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+May 20, 2024 | businesswire.comZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaMay 17, 2024 | finance.yahoo.comInsider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells SharesMay 16, 2024 | finance.yahoo.comZai Lab Announces Participation in May and June Investor ConferencesMay 16, 2024 | businesswire.comZai Lab Announces Participation in May and June Investor ConferencesMay 15, 2024 | markets.businessinsider.comAnalyst Upgrades Zai Lab’s Price Objective on Strong Drug Portfolio and Growth ProspectsMay 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), Alphatec Holdings (ATEC)See More Headlines Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,175Year FoundedN/APrice Target and Rating Average Stock Price Target$58.97 High Stock Price Target$73.34 Low Stock Price Target$38.00 Potential Upside/Downside+207.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-334,620,000.00 Net Margins-116.45% Pretax Margin-116.45% Return on Equity-40.21% Return on Assets-32.48% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.43 Sales & Book Value Annual Sales$266.72 million Price / Sales7.16 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book2.38Miscellaneous Outstanding Shares99,610,000Free Float94,399,000Market Cap$1.91 billion OptionableOptionable Beta1.06 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Ying Du Ph.D. (Age 58)Founder, Chairperson & CEO Comp: $1.67MMr. Joshua L. Smiley (Age 54)President & COO Comp: $647.11kDr. Rafael G. Amado M.D. (Age 60)President and Head of Global Oncology Research & Development Comp: $477kDr. Harald Reinhart M.D. (Age 72)President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases Comp: $923.33kDr. Yajing Chen Ph.D.Chief Financial OfficerDr. Peter Huang Ph.D.Chief Scientific OfficerMs. Christine ChiouSenior VP & Head of Investor RelationsMr. Frazor Titus Edmondson III (Age 58)J.D., Chief Legal Officer & Corporate Secretary Comp: $829kMs. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 59)Executive VP & Head of Clinical Operations More ExecutivesKey CompetitorsRevolution MedicinesNASDAQ:RVMDSummit TherapeuticsNASDAQ:SMMTElanco Animal HealthNYSE:ELANKrystal BiotechNASDAQ:KRYSOrganon & Co.NYSE:OGNView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 60,927 shares on 7/20/2024Ownership: 0.125%M&G PlcSold 16,863 shares on 7/16/2024Ownership: 0.439%Ying DuSold 7,013 sharesTotal: $122,587.24 ($17.48/share)William LisSold 10,397 sharesTotal: $180,076.04 ($17.32/share)Ying DuSold 23,939 sharesTotal: $428,508.10 ($17.90/share)View All Insider TransactionsView All Institutional Transactions ZLAB Stock Analysis - Frequently Asked Questions How have ZLAB shares performed this year? Zai Lab's stock was trading at $27.33 at the start of the year. Since then, ZLAB shares have decreased by 31.0% and is now trading at $18.86. View the best growth stocks for 2024 here. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) announced its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.38. The business earned $87.15 million during the quarter, compared to analysts' expectations of $77.07 million. Zai Lab had a negative net margin of 116.45% and a negative trailing twelve-month return on equity of 40.21%. When did Zai Lab IPO? Zai Lab (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. Who are Zai Lab's major shareholders? Top institutional shareholders of Zai Lab include M&G Plc (0.44%) and Hennion & Walsh Asset Management Inc. (0.12%). Insiders that own company stock include Ying Du, Harald Reinhart, William Lis, Joshua L Smiley, Frazor Titus Edmondson III, Yajing Chen, Peter Wirth, Tao Fu and John D Diekman. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI) and Marvell Technology (MRVL). This page (NASDAQ:ZLAB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
